Investigating how the complement system affects severe COVID-19
Role of Complement Activation in Severe COVID-19
['FUNDING_R01'] · TULANE UNIVERSITY OF LOUISIANA · NIH-10888265
This study is looking at how a part of your immune system called the complement system might cause serious problems in people with severe COVID-19, and it will test ways to change this process to see if it helps reduce damage and improve health.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TULANE UNIVERSITY OF LOUISIANA (nih funded) |
| Locations | 1 site (NEW ORLEANS, UNITED STATES) |
| Trial ID | NIH-10888265 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of the complement system in the development of severe COVID-19. It aims to explore how the activation of this immune system component contributes to complications such as endothelial damage and thrombosis in patients with severe cases of the virus. Using advanced tools, the researchers will block or modify complement activation products to study their effects on cell damage and disease progression. An animal model of severe COVID-19 will be utilized to simulate and analyze these processes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing severe COVID-19 symptoms, particularly those with acute respiratory distress syndrome.
Not a fit: Patients with mild or asymptomatic COVID-19 are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating severe COVID-19 and preventing its complications.
How similar studies have performed: Other research has indicated that targeting the complement system may provide therapeutic benefits in severe viral infections, suggesting potential success for this approach.
Where this research is happening
NEW ORLEANS, UNITED STATES
- TULANE UNIVERSITY OF LOUISIANA — NEW ORLEANS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: QIN, XUEBIN — TULANE UNIVERSITY OF LOUISIANA
- Study coordinator: QIN, XUEBIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome